Other side effects were hypertransaminasaemia (33.92%; 19), hyperbilirubinaemia (5.36%; 3), anaphylaxis (5.36%), capillary permeability syndrome (5.36%), alteration of renal function (1.78%; 1) and rash (1.78%).

Conclusion and relevance ATG treatment in paediatric patients was associated with mild side effects. ATG triggered analytical and clinically altered parameters that simulated infection and hence empirical antibiotherapy was initiated which could be stopped precociously in the event of toxic fever by ATG.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

4CPS-106 ANALYSIS OF THE PRESCRIPTION AND SAFE DRUG ADMINISTRATION OF OCRELIZUMAB

Jl García Soler*, V Arocas Casañ, L Menendez Naranjo, E Gonzalez Lozano, A Laorden Carrasco, M Díaz Ramon, JA Cano Molina, C Ramirez Roig, M Valderrey Pulido, S Vicente Sánchez. *Hospital Clínico Universitario Virgen De La Arrixaca, Pharmacy Service, Murcia, Spain*

10.1136/ejhp-2020-eahpconf.207

Background and importance Ocrelizumab is the first drug approved in Europe for the treatment of primary progressive multiple sclerosis (PPMS). It is an anti-CD20 monoclonal antibody whose use has also been authorised in early forms of PPMS and recurrent forms of MS.

Aim and objectives To evaluate the prescription of ocrelizumab and to describe its safe drug administration.

Material and methods This was a retrospective observational study of patients treated with ocrelizumab from May 2018 to March 2019. All patients who received the two initial 300 mg infusions of ocrelizumab were included. Age, sex and the variant of the disease were collected. The number of administrations of ocrelizumab and the previous use of other anti-CD20 drugs or disease modifying drugs (DMDs) were analysed. Safe drug administration was evaluated as the presence of adverse reactions during infusion or treatment according to the common terminology criteria for adverse events V5.0.

Results Twenty-seven patients were treated, 15 men (55.6%), with an average age of 49 ± 9.2 years. Nineteen patients were diagnosed with PPMS (70.4%), three with relapsing-remitting MS (22.2%) and two with secondary progressive MS (7.4%). Twenty patients were previously treated (74.1%): 14 were treated with one drug (51.9%), 5 with two drugs (18.5%) and 1 had received three different drugs previously (3.7%). One patient had previously been treated with an anti-CD20 drug (6.7%). Ocrelizumab was administered 67 times. Fourteen patients completed three administrations (51.9%). In terms of safety, nine reactions developed after infusion (13.3%): four were pruritus grade 1 (6.0%), two were palate irritation grade 1 (2.9%), two hypertensive episodes (2.9%) and one chest rash. In the first week after administration, three patients needed medical assistance due to gastrointestinal disorders, one episode of joint swelling and fever, and an influenza infection. One patient needed to be hospitalised 3 weeks after the second administration due to pericarditis.

Conclusion and relevance Ocrelizumab was used most commonly in PPMS, with the majority of patients been treated

with DMDs. Although infusional reactions appeared frequently, the incidence was less than that described in the pivotal trials. However, more experience is needed to determine the possible complications of its administration.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

4CPS-107 IMPACT OF A TOOL IN THE ELECTRONIC CLINICAL HISTORY FOR THE OPTIMISATION OF BIOLOGIC DRUGS IN RHEUMATOLOGY

M Mañes Sevilla*, EP Gómez-Caballero, B Bertran De Lis-Bartolome, I Soto Baselga, C Moriel-Sánchez. *Hospital Universitario Mostoles, Pharmacy Department, Móstoles Madrid, Spain*

10.1136/ejhp-2020-eahpconf.208

Background and importance Dosing optimisation means therapeutic benefit with the lowest possible dose for each patient, improving patient adherence and reducing adverse effects.

Aim and objectives To determine the impact of an implantation tool in the electronic medical history (ECHR) for rheumatology patients being treated with biologic drugs with or without optimisation.

Material and methods The multidisciplinary team defined optimisation strategies based on dose reduction or dosing interval. The tool was designed to be incorporated as an alert in the ECHR (Selene): 'B' for patients with biologic drugs (etanercept, infliximab, adalimumab, certolizumab, golimumab, tocilizumab, abatacept, secukinumab, baricitinib, tofacitinib, ustekinumab) and 'BO' for patients with optimised biological drugs. Eight months post-implementation, the impact of these tools on optimisation of treatments was assessed.

Results At the beginning of the study, the 'B' alert was included in the ECHR of 236 patients and 8 months later the 'B' alert was visible in 279 patients, an increase of 18%. The distribution of the drugs at the beginning and post-intervention were: etanercept (23% vs 22%), adalimumab (19% vs 21%), golimumab (14% vs 14%), certolizumab (13% vs 13%), secukinumab (9% vs 12%), infliximab (8% vs 6%), abatacept (6% vs 6%), tocilizumab (4% vs 4%), baricitinib (3% vs 2%) and tofacitinib (2% vs 3%).

For the 'BO' alert, at the beginning of the study it was included in 63 patients and in 91 patients at the end of the study, an increase of 44%. A total of 44% of patients were diagnosed with ankylosing spondylitis, 42% with rheumatoid arthritis and 14% with psoriatic arthritis. Drugs that were optimised were: adalimumab (54% vs 45%), infliximab (22% vs 14%), etanercept (21% vs 21%), certolizumab (2% vs 7%) and golimumab (3% vs 4%). This time, also optimised were: tocilizumab (3%), abatacept (1%), secukinumab (1%), tofacitinib (2%) and ustekinumab (1%). In 88% optimisation was performed by spacing of the dosing interval and in 12% by dose reduction.

Conclusion and relevance This tool has been shown to be effective in monitoring patients receiving treatment with biologic drugs and it has had a high impact on optimising these treatments.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.